Activation of fibroblasts in cancer stroma

Experimental Cell Research

Volumn 316, Issue 17, 2010, Pages 2713-2722

  Räsänen, Kati ^a   Vaheri, Antti ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cancer associated fibroblast; Nemosis; Tumor microenvironment; Tumorigenesis

Indexed keywords

CARBONATE DEHYDRATASE IX; CAVEOLIN 1; CELECOXIB; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GROWTH FACTOR; IMATINIB; INTERFERON; MARIMASTAT; MATRIX METALLOPROTEINASE; NEXAVER; PAZOPANIB; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRINOMASTAT; PROTEIN P53; SORAFENIB; SUNITINIB; SURAMIN; TANOMASTAT; TRANSCRIPTION FACTOR RUNX2; TUMOR MARKER; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VOLOCIXIMAB; VOTRIENT;

ANGIOGENESIS; BREAST CANCER; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER INVASION; CARCINOGENESIS; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONNECTIVE TISSUE; DRUG TARGETING; EXTRACELLULAR MATRIX; FIBROBLAST; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SILENCING; HUMAN; IMMUNOCOMPETENT CELL; KIDNEY CARCINOMA; LIVER CARCINOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; METABOLISM; NEOPLASMS; PARACRINE SIGNALING; PATHOLOGY; SECRETION (PROCESS); STROMA CELL;

FIBROBLASTS; HUMANS; NEOPLASMS; PARACRINE COMMUNICATION; STROMAL CELLS;

EID: 77956883321     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.04.032     Document Type: Review

References (120)

1. Axelrod R., Axelrod D.E., Pienta K.J. Evolution of cooperation among tumor cells. Proc. Natl. Acad. Sci. USA 2006, 103:13474-13479.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
3. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
4. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117:1175-1183.
5. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
6. Weinberg R.A. The Biology of Cancer 2007, Garland Science.
7. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54.
8. Polyak K., Haviv I., Campbell I.G. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009, 25:30-38.
9. Lohela M., Bry M., Tammela T., Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 2009, 21:154-165.
10. Muller-Hubenthal B., Azemar M., Lorenzen D., Huber M., Freudenberg M.A., Galanos C., Unger C., Hildenbrand B. Tumour biology: tumour-associated inflammation versus antitumor immunity. Anticancer Res. 2009, 29:4795-4805.
11. Lorusso G., Ruegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol. 2008, 130:1091-1103.
12. Broyty-Boye D. Developmental biology of fibroblasts and neoplastic disease. Developmental Biology of Neoplastic Growth 2005, Vol. 40:55-77. Springer, Berlin Heidelberg.
13. Gabbiani G., Ryan G.B., Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 1971, 27:549-550.
14. Hinz B., Gabbiani G. Mechanisms of force generation and transmission by myofibroblasts. Curr. Opin. Biotechnol. 2003, 14:538-546.
15. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 2002, 3:349-363.
16. Desmouliere A., Redard M., Darby I., Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am. J. Pathol. 1995, 146:56-66.
17. Dvorak H.F. Tumors: wounds that do not heal. similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315:1650-1659.
18. Eyden B., Banerjee S.S., Shenjere P., Fisher C. The myofibroblast and its tumours. J. Clin. Pathol. 2009, 62:236-249.
19. Trosko J.E., Ruch R.J. Cell-cell communication in carcinogenesis. Front. Biosci. 1998, 3:208-236.
20. Omori Y., Zaidan Dagli M.L., Yamakage K., Yamasaki H. Involvement of gap junctions in tumor suppression: analysis of genetically-manipulated mice. Mutat. Res. 2001, 477:191-196.
21. Orimo A., Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-1601.
22. Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., Sahai E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 2007, 9:1392-1400.
23. Chiquet M., Gelman L., Lutz R., Maier S. From mechanotransduction to extracellular matrix gene expression in fibroblasts. Biochim. Biophys. Acta 2009, 1793:911-920.
24. Kumar S., Weaver V.M. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 2009, 28:113-127.
25. Tschumperlin D.J., Dai G., Maly I.V., Kikuchi T., Laiho L.H., McVittie A.K., Haley K.J., Lilly C.M., So P.T., Lauffenburger D.A., Kamm R.D., Drazen J.M. Mechanotransduction through growth-factor shedding into the extracellular space. Nature 2004, 429:83-86.
26. Hinz B., Phan S.H., Thannickal V.J., Galli A., Bochaton-Piallat M.L., Gabbiani G. The myofibroblast: one function, multiple origins. Am. J. Pathol. 2007, 170:1807-1816.
27. McAnulty R.J. Fibroblasts and myofibroblasts: their source, function and role in disease. Int. J. Biochem. Cell Biol. 2007, 39:666-671.
28. Östman A., Augsten M. Cancer-associated fibroblasts and tumor growth - bystanders turning into key players. Curr. Opin. Genet. Dev. 2009, 19:97-73.
29. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.
30. Potenta S., Zeisberg E., Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br. J. Cancer 2008, 99:1375-1379.
31. Coppe J.P., Desprez P.Y., Krtolica A., Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 2010, 5:99-118.
32. Haviv I., Polyak K., Qiu W., Hu M., Campbell I. Origin of carcinoma associated fibroblasts. Cell Cycle 2009, 8:589-595.
33. Tsellou E., Kiaris H. Fibroblast independency in tumors: implications in cancer therapy. Future Oncol. 2008, 4:427-432.
34. Sugimoto H., Mundel T.M., Kieran M.W., Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. 2006, 5:1640-1646.
35. Räsänen K., Virtanen I., Salmenperä P., Grenman R., Vaheri A. Differences in the nemosis response of normal and cancer-associated fibroblasts from patients with oral squamous cell carcinoma. PLoS ONE 2009, 4:e6879.
36. Erez N., Truitt M., Olson P., Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010, 17:135-147.
37. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
38. Östman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 2004, 15:275-286.
39. Sherbet G.V. Metastasis promoter S100A4 is a potentially valuable molecular target for cancer therapy. Cancer Lett. 2009, 280:15-30.
40. Mathew S., Scanlan M.J., Mohan Raj B.K., Murty V.V., Garin-Chesa P., Old L.J., Rettig W.J., Chaganti R.S. The gene for fibroblast activation protein alpha (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. Genomics 1995, 25:335-337.
41. O'Brien P., O'Connor B.F. Seprase: an overview of an important matrix serine protease. Biochim. Biophys. Acta 2008, 1784:1130-1145.
42. Micke P., Östman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?. Lung Cancer 2004, 45(Suppl 2):S163-S175.
43. Qiu W., Hu M., Sridhar A., Opeskin K., Fox S., Shipitsin M., Trivett M., Thompson E.R., Ramakrishna M., Gorringe K.L., Polyak K., Haviv I., Campbell I.G. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat. Genet. 2008, 40:650-655.
44. Campbell I., Polyak K., Haviv I. Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. Cancer Res. 2009, 69:6765-6768.
45. Lin H.J., Zuo T., Chao J.R., Peng Z., Asamoto L.K., Yamashita S.S., Huang T.H. Seed in soil, with an epigenetic view. Biochim. Biophys. Acta 2009, 1790:920-924.
46. Nyberg P., Salo T., Kalluri R. Tumor microenvironment and angiogenesis. Front. Biosci. 2008, 13:6537-6553.
47. De Wever O., Demetter P., Mareel M., Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int. J. Cancer 2008, 123:2229-2238.
48. Paulsson J., Sjoblom T., Micke P., Ponten F., Landberg G., Heldin C.H., Bergh J., Brennan D.J., Jirstrom K., Östman A. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am. J. Pathol. 2009, 175:334-341.
49. Nakao M., Ishii G., Nagai K., Kawase A., Kenmotsu H., Kon-No H., Hishida T., Nishimura M., Yoshida J., Ochiai A. Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma. Cancer 2009, 115:2732-2743.
50. Chuaysri C., Thuwajit P., Paupairoj A., Chau-In S., Suthiphongchai T., Thuwajit C. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol. Rep. 2009, 21:957-969.
51. Ruan K., Bao S., Ouyang G. The multifaceted role of periostin in tumorigenesis. Cell. Mol. Life Sci. 2009, 66:2219-2230.
52. Utispan K., Thuwajit P., Abiko Y., Charngkaew K., Paupairoj A., Chau-In S., Thuwajit C. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol. Cancer 2010, 9:13.
53. Hooper S., Gaggioli C., Sahai E. A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion. Br. J. Cancer 2010, 102:392-402.
54. Goetz J.G., Lajoie P., Wiseman S.M., Nabi I.R. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008, 27:715-735.
55. Witkiewicz A.K., Dasgupta A., Sotgia F., Mercier I., Pestell R.G., Sabel M., Kleer C.G., Brody J.R., Lisanti M.P. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am. J. Pathol. 2009, 174:2023-2034.
56. Di Vizio D., Morello M., Sotgia F., Pestell R.G., Freeman M.R., Lisanti M.P. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial akt activation. Cell Cycle 2009, 8:2420-2424.
57. Sloan E.K., Ciocca D.R., Pouliot N., Natoli A., Restall C., Henderson M.A., Fanelli M.A., Cuello-Carrion F.D., Gago F.E., Anderson R.L. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am. J. Pathol. 2009, 174:2035-2043.
58. Yamanashi T., Nakanishi Y., Fujii G., Akishima-Fukasawa Y., Moriya Y., Kanai Y., Watanabe M., Hirohashi S. Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma. Oncology 2009, 77:53-62.
59. Mueller M.M., Fusenig N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4:839-849.
60. Roy R., Yang J., Moses M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 2009, 27:5287-5297.
61. Hynes R.O. The extracellular matrix: not just pretty fibrils. Science 2009, 326:1216-1219.
62. Vosseler S., Lederle W., Airola K., Obermueller E., Fusenig N.E., Mueller M.M. Distinct progression-associated expression of tumor and stromal MMPs in HaCaT skin SCCs correlates with onset of invasion. Int. J. Cancer 2009, 125:2296-2306.
63. Lederle W., Hartenstein B., Meides A., Kunzelmann H., Werb Z., Angel P.P., Mueller M.M. MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis 2009, 31:1175-1184.
64. Zigrino P., Kuhn I., Bauerle T., Zamek J., Fox J.W., Neumann S., Licht A., Schorpp-Kistner M., Angel P., Mauch C. Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J. Investig. Dermatol. 2009, 129:2686-2693.
65. G. Gaud, S. Iochmann, A. Guillon-Munos, B. Brillet, S. Petiot, F. Seigneuret, A. Touze, N. Heuze-Vourc'h, Y. Courty, S. Lerondel, Y. Gruel, P. Reverdiau, in press. TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions, J. Cell. Mol. Med. doi:10.1111/j.1582-4934.2009.00989.x.
66. Santos A.M., Jung J., Aziz N., Kissil J.L., Pure E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 2009, 119:3613-3625.
67. Liao D., Luo Y., Markowitz D., Xiang R., Reisfeld R.A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE 2009, 4:e7965.
68. A.M. Lebeau, W.N. Brennen, S. Aggarwal, S.R. Denmeade, in press. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin, Mol. Cancer. Ther. http://doi:10.1158/1535-7163.MCT-08-1170.
69. Blasi F., Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 2010, 584:1923-1930.
70. Dano K., Behrendt N., Hoyer-Hansen G., Johnsen M., Lund L.R., Ploug M., Romer J. Plasminogen activation and cancer. Thromb. Haemost. 2005, 93:676-681.
71. Noskova V., Ahmadi S., Asander E., Casslen B. Ovarian cancer cells stimulate uPA gene expression in fibroblastic stromal cells via multiple paracrine and autocrine mechanisms. Gynecol. Oncol. 2009, 115:121-126.
72. Stoker M., Perryman M. An epithelial scatter factor released by embryo fibroblasts. J. Cell Sci. 1985, 77:209-223.
73. Nakamura T., Teramoto H., Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc. Natl. Acad. Sci. USA 1986, 83:6489-6493.
74. Benvenuti S., Comoglio P.M. The MET receptor tyrosine kinase in invasion and metastasis. J. Cell. Physiol. 2007, 213:316-325.
75. Peruzzi B., Bottaro D.P. Targeting the c-met signaling pathway in cancer. Clin. Cancer Res. 2006, 12:3657-3660.
76. Wang W., Li Q., Yamada T., Matsumoto K., Matsumoto I., Oda M., Watanabe G., Kayano Y., Nishioka Y., Sone S., Yano S. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin. Cancer Res. 2009, 15:6630-6638.
77. Jedeszko C., Victor B.C., Podgorski I., Sloane B.F. Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer Res. 2009, 69:9148-9155.
78. Mazzocca A., Fransvea E., Dituri F., Lupo L., Antonaci S., Giannelli G. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 2010, 51:532-534.
79. Chen C.C., Lau L.F. Functions and mechanisms of action of CCN matricellular proteins. Int. J. Biochem. Cell Biol. 2009, 41:771-783.
80. Massague J. TGFbeta in cancer. Cell 2008, 134:215-230.
81. Mumm J.B., Oft M. Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. Oncogene 2008, 27:5913-5919.
82. Murugaiyan G., Saha B. Protumor vs antitumor functions of IL-17. J. Immunol. 2009, 183:4169-4175.
83. Gerber P.A., Hippe A., Buhren B.A., Muller A., Homey B. Chemokines in tumor-associated angiogenesis. Biol. Chem. 2009, 390:1213-1223.
84. Augsten M., Hagglof C., Olsson E., Stolz C., Tsagozis P., Levchenko T., Frederick M.J., Borg A., Micke P., Egevad L., Östman A. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc. Natl. Acad. Sci. USA 2009, 106:3414-3419.
85. Matsuo Y., Ochi N., Sawai H., Yasuda A., Takahashi H., Funahashi H., Takeyama H., Tong Z., Guha S. CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int. J. Cancer 2009, 124:853-861.
86. D.W. Jung, Z.M. Che, J. Kim, K. Kim, K.Y. Kim, D. Williams, J. Kim, in press. Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7, Int. J. Cancer. http://doi:10.1002/ijc.25060.
87. Rossi D., Zlotnik A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 2000, 18:217-242.
88. Lu Y., Yang W., Qin C., Zhang L., Deng J., Liu S., Qin Z. Responsiveness of stromal fibroblasts to IFN-gamma blocks tumor growth via angiostasis. J. Immunol. 2009, 183:6413-6421.
89. Balsamo M., Scordamaglia F., Pietra G., Manzini C., Cantoni C., Boitano M., Queirolo P., Vermi W., Facchetti F., Moretta A., Moretta L., Mingari M.C., Vitale M. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc. Natl. Acad. Sci. USA 2010, 106:20847-20852.
90. Junttila M.R., Evan G.I. p53-a jack of all trades but master of none. Nat. Rev. Cancer 2009, 9:821-829.
91. Patocs A., Zhang L., Xu Y., Weber F., Caldes T., Mutter G.L., Platzer P., Eng C. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N. Engl. J. Med. 2007, 357:2543-2551.
92. Hasebe T., Tamura N., Okada N., Hojo T., Akashi-Tanaka S., Shimizu C., Tsuda H., Shibata T., Sasajima Y., Iwasaki M., Kinoshita T. P53 expression in tumor-stromal fibroblasts is closely associated with the nodal metastasis and outcome of patients with invasive ductal carcinoma who received neoadjuvant therapy. Hum. Pathol. 2010, 41:262-270.
93. Trimboli A.J., Cantemir-Stone C.Z., Li F., Wallace J.A., Merchant A., Creasap N., Thompson J.C., Caserta E., Wang H., Chong J.L., Naidu S., Wei G., Sharma S.M., Stephens J.A., Fernandez S.A., Gurcan M.N., Weinstein M.B., Barsky S.H., Yee L., Rosol T.J., Stromberg P.C., Robinson M.L., Pepin F., Hallett M., Park M., Ostrowski M.C., Leone G. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009, 461:1084-1091.
94. Greenhough A., Smartt H.J., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
95. Banu S.K., Lee J., Speights V.O., Starzinski-Powitz A., Arosh J.A. Cyclooxygenase-2 regulates survival, migration, and invasion of human endometriotic cells through multiple mechanisms. Endocrinology 2008, 149:1180-1189.
96. Räsänen K., Vaheri A. TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes. J. Dermatol. Sci. 2010, 58:97-104.
97. Hyde C.A., Missailidis S. Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. Int. Immunopharmacol. 2009, 9:701-715.
98. Wang J., Ying G., Wang J., Jung Y., Lu J., Zhu J., Pienta K.J., Taichman R.S. Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. Cancer Res. 2010, 70:471-480.
99. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
100. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
101. Pavlides S., Whitaker-Menezes D., Castello-Cros R., Flomenberg N., Witkiewicz A.K., Frank P.G., Casimiro M.C., Wang C., Fortina P., Addya S., Pestell R.G., Martinez-Outschoorn U.E., Sotgia F., Lisanti M.P. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009, 8:3984-4001.
102. Food and Drug Administration []. http://www.fda.gov/drugs.
103. Laplant K.D., Louzon P.D. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma. Ann. Pharmacother. 2010, 44:1054-1066.
104. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10:9-22.
105. Tu G., Xu W., Huang H., Li S. Progress in the development of matrix metalloproteinase inhibitors. Curr. Med. Chem. 2008, 15:1388-1395.
106. Scott A.M., Wiseman G., Welt S., Adjei A., Lee F.T., Hopkins W., Divgi C.R., Hanson L.H., Mitchell P., Gansen D.N., Larson S.M., Ingle J.N., Hoffman E.W., Tanswell P., Ritter G., Cohen L.S., Bette P., Arvay L., Amelsberg A., Vlock D., Rettig W.J., Old L.J. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 2003, 9:1639-1647.
107. Hofheinz R.D., al-Batran S.E., Hartmann F., Hartung G., Jager D., Renner C., Tanswell P., Kunz U., Amelsberg A., Kuthan H., Stehle G. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 2003, 26:44-48.
108. Ulisse S., Baldini E., Sorrenti S., D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr. Cancer Drug Targets 2009, 9:32-71.
109. Rosen P.J., Sweeney C.J., Park D.J., Beaupre D.M., Deng H., Leitch I.M., Shubhakar P., Zhu M., Oliner K.S., Anderson A., Yee L.K. A phase ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin. Cancer Res. 2010, 16:2677-2687.
110. Hsu J.Y., Wakelee H.A. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 2009, 23:289-304.
111. Harris R.E., Beebe-Donk J., Alshafie G.A. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell. Biochem. 2007, 42:193-212.
112. Rhee S. Fibroblasts in three dimensional matrices: cell migration and matrix remodeling. Exp. Mol. Med. 2009, 41:858-865.
113. Vaheri A., Enzerink A., Räsänen K., Salmenperä P. Nemosis, a novel way of fibroblast activation, in inflammation and cancer. Exp. Cell Res. 2009, 315:1633-1638.
114. Salmenperä P., Kankuri E., Bizik J., Siren V., Virtanen I., Takahashi S., Leiss M., Fassler R., Vaheri A. Formation and activation of fibroblast spheroids depend on fibronectin-integrin interaction. Exp. Cell Res. 2008, 314:3444-3452.
115. Kankuri E., Cholujova D., Comajova M., Vaheri A., Bizik J. Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotes tumor cell invasiveness. Cancer Res. 2005, 65:9914-9922.
116. K. Räsänen, A. Vaheri, in press. Proliferation and motility of HaCaT keratinocyte derivatives is enhanced by fibroblast nemosis, Exp. Cell Res. http://doi:10.1016/j.yexcr.2010.01.020.
117. Kankuri E., Babusikova O., Hlubinova K., Salmenperä P., Boccaccio C., Lubitz W., Harjula A., Bizik J. Fibroblast nemosis arrests growth and induces differentiation of human leukemia cells. Int. J. Cancer 2008, 122:1243-1252.
118. Enzerink A., Salmenperä P., Kankuri E., Vaheri A. Clustering of fibroblasts induces proinflammatory chemokine secretion promoting leukocyte migration. Mol. Immunol. 2009, 46:1787-1795.
119. Enzerink A., Rantanen V., Vaheri A. Fibroblast nemosis induces angiogenic responses of endothelial cells. Exp. Cell Res. 2010, 316:826-835.
120. Räsänen K., Salmenperä P., Baumann M., Virtanen I., Vaheri A. Nemosis of fibroblasts is inhibited by benign HaCaT keratinocytes but promoted by malignant HaCaT cells. Mol. Oncol. 2008, 2:340-348.